Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Insulin resistance precedes dyslipidemia and type 2 diabetes mellitus (T2DM) development. Preclinical evidence suggests that peroxisome proliferator-activated receptor (PPAR) β/δ activators may prevent and treat obesity-induced insulin resistance and T2DM, while clinical trials highlight their potential utility in dyslipidemia. This review summarizes recent mechanistic insights into the antidiabetic effects of PPARβ/δ activators, including their anti-inflammatory actions, their ability to inhibit endoplasmic reticulum (ER) stress and hepatic lipogenesis, and to improve atherogenesis and insulin sensitivity, as well as their capacity to activate pathways that are also stimulated by exercise. Findings from clinical trials are also examined. Dissecting the effects of PPARβ/δ ligands on insulin sensitivity and atherogenesis may provide a basis for the development of therapies for the prevention and treatment of T2DM and cardiovascular disease (CVD).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 1×
“Insulin resistance, a hallmark of T2DM, encompasses a defect in glucose uptake into insulin target tissues, accompanied by suppression of hepatic glucose output and aberrant regulation of lipolysis [2].”
BackgroundPeroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity
Wang, Y.-X., Lee, C.-H., Tiep, S., Yu, R. T., Ham, J., Kang, H., & Evans, R. M. (2003) · Cell · doi:10.1016/s0092-8674(03)00269-1 · Cited by 1,296
Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance
Pal, D., Dasgupta, S., Kundu, R., Maitra, S., Das, G., Mukhopadhyay, S., Ray, S., Majumdar, S. S., & Bhattacharya, S. (2012) · Nature Medicine · doi:10.1038/nm.2851 · Cited by 922 · cited 1×
“Part of the proinflammatory effects of SFAs are mediated by the activation of Toll-like receptor 4 (TLR4) and require the presence of its endogenous ligand, fetuin A, because removing either of them prevents FA-induced inflammation and insulin resistance in adipocytes [27].”
BackgroundMetabolically healthy obesity: Epidemiology, mechanisms, and clinical implications
Stefan, N., Häring, H.-U., Hu, F. B., & Schulze, M. B. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70062-7 · Cited by 857
Kang, K., Reilly, S. M., Karabacak, V., Gangl, M. R., Fitzgerald, K., Hatano, B., & Lee, C.-H. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.04.002 · Cited by 699
Regulation of metabolism by the innate immune system
Lackey, D. E., & Olefsky, J. M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.189 · Cited by 667
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440 · cited 2×
“A major cause of CVD in T2DM is atherogenic dyslipidemia [61], initiated by hepatic overproduction of TG-rich lipoproteins and very low density lipoprotein (VLDL) overproduction, leading to a reduction in high-density lipoprotein (HDL)-cholesterol and an increase in small dense low-density lipoprotein (LDL) particles…”
BackgroundPioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
Lewis, J. D., Habel, L. A., Quesenberry, C. P., Strom, B. L., Peng, T., Hedderson, M. M., Ehrlich, S. F., Mamtani, R., Bilker, W., Vaughn, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.7996 · Cited by 320
Hypoxia and Adipocyte Physiology: Implications for Adipose Tissue Dysfunction in Obesity
Trayhurn, P. (2014) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071812-161156 · Cited by 194 · cited 1×
“The vascular infrastructure generally does not keep pace with the rapid tissue expansion during obesity, leading to local hypoxia [94].”
BackgroundPhysiological functions of peroxisome proliferator-activated receptor β
Neels, J. G., & Grimaldi, P. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00027.2013 · Cited by 161
Cited by
Han, L., Shen, W.-J., Bittner, S., Kraemer, F. B., & Azhar, S. (2017) · Future Cardiology · doi:10.2217/fca-2017-0019 · Cited by 256
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Hong, F., Pan, S., Guo, Y., Xu, P., & Zhai, Y. (2019) · Molecules · doi:10.3390/molecules24142545 · Cited by 233
Protective Effects of (E)-β-Caryophyllene (BCP) in Chronic Inflammation
Scandiffio, R., Geddo, F., Cottone, E., Querio, G., Antoniotti, S., Gallo, M. P., Maffei, M. E., & Bovolin, P. (2020) · Nutrients · doi:10.3390/nu12113273 · Cited by 177
“PPARβ/δ is expressed in skeletal muscle, heart, gastrointestinal tract, adipose tissue, where it regulates fatty acid metabolism [81].”
BackgroundHong, F., Xu, P., & Zhai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082189 · Cited by 139
PPARβ/δ selectively regulates phenotypic features of age-related macular degeneration
Choudhary, M., Ding, J.-D., Qi, X., Boulton, M. E., Yao, P.-L., Peters, J. M., & Malek, G. (2016) · Aging · doi:10.18632/aging.101031 · Cited by 39
Metadata
- Authors
- Vázquez-Carrera, M.
- Venue
- Trends in Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 27
- Issue
- 5
- Pages
- 319-334
- ISSN
- 1043-2760 (ISSN-L)
- OpenAlex
- W2302434278
- Cited by
- 71
- References
- 18
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease. https://app.cochat.ai/papers/10.1016/j.tem.2016.02.008
- The paper
- Vázquez-Carrera, M. (2016). Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease. Trends in Endocrinology & Metabolism. https://doi.org/10.1016/j.tem.2016.02.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.